Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

126.56
-4.4800-3.42%
Post-market: 126.560.00000.00%19:59 EDT
Volume:1.15M
Turnover:147.49M
Market Cap:18.54B
PE:12.51
High:130.70
Open:130.27
Low:126.49
Close:131.04
Loading ...

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?

Zacks
·
14 Mar

Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
12 Mar

Biogen Initiates Dosing of Phase 3 Study of Felzartamab

MT Newswires Live
·
11 Mar

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

Zacks
·
11 Mar

Biogen announces initiation of dosing in TRANSCEND

TIPRANKS
·
11 Mar

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

GlobeNewswire
·
11 Mar

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-03-10

Reuters
·
10 Mar

Unusually active option classes on open March 10th

TIPRANKS
·
10 Mar

BUZZ- Some defensives outperform, even as indexes switch to gains

Reuters
·
08 Mar

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-03-07

Reuters
·
08 Mar

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Zacks
·
07 Mar

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
07 Mar

Biogen (BIIB) Receives a Hold from Bernstein

TIPRANKS
·
06 Mar

Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'

Blockhead
·
03 Mar

Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia

MT Newswires Live
·
03 Mar

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

StockStory
·
03 Mar

As baby boomers turn 80, there aren't enough doctors to treat 'emergency levels' of dementia patients

Dow Jones
·
01 Mar

Pfizer quietly made some big DEI changes

Quartz
·
01 Mar

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Dow Jones
·
28 Feb

Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab

MT Newswires Live
·
28 Feb